---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-427829"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2026-10-21T20:09:43+00:00"
generated_at: "2026-10-21T20:12:21.214438+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences pegs Sept 30, 2026 cash and marketable securities at ~$694.0M

## Summary
- Preliminary estimate of approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.
- Filing discloses no revenue, EPS, burn rate or cash runway figures; it is a cash-balance update only.
- Estimate is unaudited and subject to completion of financial closing procedures; Ernst & Young has not audited, reviewed or compiled the figure.
- Company cautions the balance may vary from the actual September 30, 2026 position and is not indicative of future periods.

## SEC filing metadata
- accession: 0001193125-26-427829
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2026-10-21T20:09:43+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000119312526427829/0001193125-26-427829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000119312526427829/d130368d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-427829
- JSON: https://secwatch.observer/filing/0001193125-26-427829.json
- Plain text: https://secwatch.observer/filing/0001193125-26-427829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.